SCHEMBL5924902

SCHEMBL5924902

O=C(O)c1cc(-c2ccco2)cc(-c2ccco2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.74
PTPN1 P18031 1/20 0.54
MEN1 O00255 2/20 0.51
POLB P06746 2/20 0.51
MAPT P10636 2/20 0.51
KMT2A Q03164 2/20 0.51
NSD2 O96028 1/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
THRB P10828 1/20 0.51
PABPC1 P11940 1/20 0.51
TNNI3 P19429 1/20 0.51
TNNT2 P45379 1/20 0.51
TNNC1 P63316 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
EGLN1 Q9GZT9 1/20 0.48
CREBBP Q92793 2/20 0.47
TRIM24 O15164 1/20 0.47
BRD4 O60885 1/20 0.47
EP300 Q09472 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31151058 0.96 KEAP1 (0.74) KEAP1PTPN1MEN1POLBMAPT
SCHEMBL18304658 0.88 KEAP1 (0.64) KEAP1PTPN1MEN1POLBMAPT
SCHEMBL18304656 0.88 KEAP1 (0.64) KEAP1PTPN1MEN1POLBMAPT
SCHEMBL2723466 0.88 KEAP1 (0.64) KEAP1PTPN1MEN1POLBMAPT
SCHEMBL18304663 0.88 KEAP1 (0.64) KEAP1PTPN1MEN1POLBMAPT
SCHEMBL18304652 0.85 KAT6A (0.61) KEAP1PTPN1MEN1POLBMAPT
SCHEMBL941410 0.85 KEAP1 (1.00) KEAP1PTPN1MEN1POLBMAPT
SCHEMBL28666592 0.85 KEAP1 (0.74) KEAP1PTPN1MEN1POLBMAPT
SCHEMBL4682626 0.82 KEAP1 (0.66) KEAP1PTPN1MEN1POLBMAPT
SCHEMBL17729031 0.81 KEAP1 (0.64) KEAP1PTPN1MEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122184-A1 Cyanomethyl derivatives as cysteine protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2006-06-08 US disclosed
US-20050288336-A1 Cysteine protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-12-29 US disclosed
EP-1569954-A1 CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-09-07 EP disclosed
EP-1503997-A1 CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-02-09 EP disclosed
WO-2004052921-A1 CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-06-24 WO disclosed
WO-2003097617-A1 CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122184-A1 Cyanomethyl derivatives as cysteine protease inhibitors CTSF, CTSB, CTSK KEAP1 429/4885PTPN1 2971/4885MEN1 3944/4885
US-20050288336-A1 Cysteine protease inhibitors CTSF, CTSS, CTSB KEAP1 433/4885PTPN1 3660/4885MEN1 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.